Company
Affinia Therapeutics
We see what’s possible tomorrow for patients by creating it today
Also known as Affinia Therapeutics, Inc., Affiniatx
- Business model
- B2B
- Headquarters
- Waltham, MA, United States
- Legal name
- Affinia Therapeutics, Inc.
- affiniatx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
There’s a new frontier in the fight against devastating rare and prevalent diseases, and Affinia Therapeutics is pioneering the way. We’re expanding what’s possible with adeno-associated virus (AAV) gene therapy, starting with diseases of the heart and of the nervous system.
Funding snapshot
- Total raised
- $170MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series C, $40M2025-10-08
Funding rounds
- Series C
- $40M2025-10-08, Announced
- Round, 2025
- $13.3M2025-09-16, SEC form D sold, 20 investors
- Round, 2021
- $110M2021-04-20, SEC form D sold, 22 investors
- Series A
- $60M2020-04-01, Announced
- Round, 2020
- $38.5M2020-03-12, SEC form D sold, 16 investors
- Round, 2019
- $8.3M2019-10-22, SEC form D sold, 14 investors
Products
- Web
- AFTX-201
Loading relationship preview